Fritextsökning
Innehållstyper
-
Orexo får USA-stöd för överdosläkemedel vid blandmissbruk
Uppsalabolaget Orexo har fått 8 miljoner dollar, motsvarande 75 miljoner kronor, av den amerikanska myndigheten Barda för att ta fram ett nasalt räddningsläkeme...
-
Gothenburg, the city of life science – We are ‘Little Boston’
Western Sweden is investing in life science within everything from advanced therapeutic drugs to femtech. At the same time, stakeholders are looking to other in...
-
Conference on Alzheimer’s reveals several advances in the field
In Gothenburg, Sweden, researchers and pharmaceutical companies from all over the world gathered to discuss one specific issue – neurological diseases. Life Sci...
-
Nobel Prize winner Torsten Wiesel turns 100: “Old men like me should use their experience to help the young”
In 1955, a young Torsten Wiesel jumped on a boat to the US and embarked on a fabulous career as a neuroscientist, crowned with a Nobel Prize for his work. Now 1...
-
The key to successful collaboration between industry and academia
Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?
-
Bioscience – Groundbreaking Research & Diagnostics: Gothenburg (2026)
-
Meet us at Control 2025
Innovations that drive efficiency.
-
ZEN core now available for all ZEISS scanning electron microscopes
Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.
-
Microscope and measuring machine in one
ZEISS O-INSPECT duo covers two essential applications in quality assurance.
-
Come see us at the upcoming events!
We have some upcoming events where you can see our latest products live!
-
Sofia Wallström is Lif's new CEO
Sofia Wallström has been appointed as the new CEO of the industry organization Lif, the trade association for the research-based pharmaceutical industry in Sweden.
-
The first drugs to slow down Alzheimer’s – but what does it mean for patients?
New treatments for early Alzheimer’s are bringing hope to thousands of patients and their families. The question is, who will get the treatment, how will the ri...
-
The government proposes fines for pharmaceutical companies that fail to notify drug shortages in time
According to a compilation from the Swedish Medicines Agency, the number of residually notified medicines increased by 54 % in Sweden last year compared to the ...
-
ZEISS presents the "Quality Innovation Summit"
A global event on the future of quality assurance.
-
Kokainberoende råttor knarkade mindre med semaglutid
Läkemedel som innehåller semaglutid minskade suget hos kokainberoende råttor i en studie från Göteborgs universitet.
-
Revealing the secrets of a part
CT inspection in automation technology at Festo.
-
Grönt ljus för Kennedy sänker läkemedelsbolag
Flera läkemedelsbolag backar på börsen efter att senatskommittén godkänt Robert F. Kennedy Jr som kandidat till landets hälsominister.
-
Faster development of reliable sample handling
to integrate into the customer's platform – with standard components from Festo, a PerkinElmer® JANUS G3 workstation and a modified rotary gripper module. This ...
-
A new giant among our microscopes
Two technologies in one machine.
-
Extensive agreements signed at Scilifelab
Four agreements were signed between Swedish and Dutch life science players in connection with the Dutch state visit earlier this month.
-
How critical are the “Spermageddon” reports? – Researchers call for action
A much talked about meta-study indicates that sperm concentration in men’s seminal fluid has halved in 40 years. Experts in andrology that Life Science Sweden s...
-
Forskaren in Hagastaden now inagurated
The real estate company Vectura's life science center in Hagastaden, Forskaren, is now inaugurated. The opening was attended by people from the industry, politi...
-
Thomas Eldered: ”Innovation is the key”
Thomas Eldered speaks in a web clip about the challenges facing the life science sector in the future and what he, as an investor, finds most interesting in new companies.
-
EMA review confirms a risk of new cancer after CAR-T
CAR-T cancer therapies can, in rare cases, induce secondary cancers. The European Medicines Agency (EMA) now recognises this and requires a warning label to be ...